Autolus Therapeutics (NASDAQ:AUTL) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note released on Monday,Benzinga reports. Needham & Company LLC currently has a $9.00 target price on the stock.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock opened at $3.01 on Monday. The stock has a market capitalization of $800.94 million, a price-to-earnings ratio of -2.49 and a beta of 2.04. The firm’s 50-day moving average price is $3.92 and its two-hundred day moving average price is $3.99. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. Autolus Therapeutics has a 1-year low of $2.98 and a 1-year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the company posted ($0.26) earnings per share. On average, equities analysts predict that Autolus Therapeutics will post -0.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Erste Asset Management GmbH bought a new stake in Autolus Therapeutics during the 3rd quarter worth about $708,000. Bellevue Group AG lifted its position in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares in the last quarter. Capstone Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the third quarter valued at approximately $51,000. FMR LLC grew its stake in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares during the last quarter. Finally, HealthInvest Partners AB increased its holdings in shares of Autolus Therapeutics by 95.6% in the third quarter. HealthInvest Partners AB now owns 442,423 shares of the company’s stock valued at $1,606,000 after purchasing an additional 216,278 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.